Evidence map›Paper›PMID 36820285›Full record

ArticleYonago acta medica2023

Development of a Prognostic Scoring System using MYC Expression and Soluble Interleukin Receptor -2 level for Diffuse Large B-cell Lymphoma.

Sayaka Suzuki, Satoshi Kuwamoto, Koji Kawamura, Michiko Matsushita, Toru Motokura, Yuzuru Hosoda, Masaya Maegaki, Rina Hosoda, Kentaro Hara, Yoshihisa Umekita and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Yonago acta medica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Sayaka SuzukiDepartment of Hematology, Tottori University Hospital, Yonago 683-8504, Japan.
Satoshi KuwamotoDepartment of Pathology, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan.
Koji KawamuraDepartment of Hematology, Tottori University Hospital, Yonago 683-8504, Japan.
Michiko MatsushitaDepartment of Pathobiological Science and Technology, School of Health Science, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan.
Toru MotokuraDivision of Clinical Laboratory Medicine, Department of Multidisciplinary Internal Medicine, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan.
Yuzuru HosodaDepartment of Hematology, Tottori University Hospital, Yonago 683-8504, Japan.
Masaya MaegakiDepartment of Hematology, Tottori University Hospital, Yonago 683-8504, Japan.
Rina HosodaDepartment of Hematology, Tottori University Hospital, Yonago 683-8504, Japan.
Kentaro HaraDepartment of Hematology, Tottori University Hospital, Yonago 683-8504, Japan.
Yoshihisa UmekitaDepartment of Pathology, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan.
Tetsuya FukudaDepartment of Hematology, Tottori University Hospital, Yonago 683-8504, Japan.
Tottori University · JPTottori University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS), is the most frequent type of lymphoid neoplasm. Methods: We investigated the relationships between clinical factors of DLBCL-NOS and MYC immunohistochemistry (IHC) staining. Results: A total of 110 patients diagnosed with DLBCL-NOS from 2012 to 2020 at Tottori University Hospital and treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy were included. IHC staining of MYC in formalin-fixed, paraffin-embedded tumor specimens was performed, and ROC-curve analysis revealed the cut-off value of the MYC positive rate as 55%. The 2-year overall survival (OS) rates of the MYC-negative and -positive groups were 84.7% vs 57.7% ( Conclusion: We suggest that a prognostic scoring system using MYC expression and soluble interleukin receptor -2 level is useful for the prediction of prognosis, contributing to further stratification in DLBCL-NOS.

Indexed as

diffuse large B-cell lymphomaimmunohistochemistryMYCnon-Hodgkin lymphomanot otherwise specifiedProto-Oncogene ProteinsR-CHOP chemotherapy

Identifiers

PMID36820285
PMCPMC9937959
OpenAlexW4317861989

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.